UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cardiovascular effects of gliptins

Nature reviews cardiology, 2013-02, Vol.10 (2), p.73-84

Scheen, André J

2013

Volltextzugriff (PDF)

Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue

Diabetologia, 2013-11, Vol.56 (11), p.2487-2497

2013

Volltextzugriff (PDF)

Dipeptidylpeptitase-4 Inhibitors (Gliptins): Focus on Drug-Drug Interactions

Clinical Pharmacokinetics, 2010-09, Vol.49 (9), p.573-588

SCHEEN, André J

2010

Volltextzugriff (PDF)

Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease

Expert opinion on drug metabolism & toxicology, 2013-05, Vol.9 (5), p.529-550

Scheen, André J

2013

Volltextzugriff (PDF)

Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations

Expert opinion on drug metabolism & toxicology, 2014-05, Vol.10 (5), p.647-663

Scheen, André J

2014

Volltextzugriff (PDF)

SGLT2 Inhibitors as Add-On Therapy to Metformin for People with Type 2 Diabetes: A Review of Placebo-Controlled Trials in Asian versus Non-Asian Patients

Diabetes, metabolic syndrome and obesity, 2020-01, Vol.13, p.2765-2779

Scheen, André J

2020

Volltextzugriff (PDF)

Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease

Expert opinion on drug metabolism & toxicology, 2014-06, Vol.10 (6), p.839-857

Scheen, André J

2014

Volltextzugriff (PDF)

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

Diabetes/metabolism research and reviews, 2010-10, Vol.26 (7), p.540-549

2010

Volltextzugriff (PDF)

Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus

Drugs (New York, N.Y.), 2015-01, Vol.75 (1), p.33-59

Scheen, André J.

2015

Volltextzugriff (PDF)

Sibutramine on cardiovascular outcome

Diabetes care, 2011-05, Vol.34 Suppl 2 (5), p.S114-S119

Scheen, André J

2011

Volltextzugriff (PDF)

Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system

Drugs (New York, N.Y.), 2004-01, Vol.64 (22), p.2537-2565

SCHEEN, André J

2004

Volltextzugriff (PDF)

Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors

Circulation research, 2018-05, Vol.122 (10), p.1439-1459

Scheen, André J

2018

Volltextzugriff (PDF)

Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus

Nature reviews. Endocrinology, 2020-10, Vol.16 (10), p.556-577

Scheen, André J

2020

Volltextzugriff (PDF)

Time for reconciliation between cardiologists and diabetologists

Nature reviews cardiology, 2016-09, Vol.13 (9), p.509-510

Scheen, André J.

2016

Volltextzugriff (PDF)

Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor

Clinical pharmacokinetics, 2014-03, Vol.53 (3), p.213-225

Scheen, André J.

2014

Volltextzugriff (PDF)

Is there a role for α-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?

Drugs (New York, N.Y.), 2003-01, Vol.63 (10), p.933-951

SCHEEN, André J

2003

Volltextzugriff (PDF)

Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes

Expert opinion on drug metabolism & toxicology, 2015-06, Vol.11 (6), p.1005-1020

Scheen, André J

2015

Volltextzugriff (PDF)

Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes

Diabetes research and clinical practice, 2014-08, Vol.105 (2), p.141-150

2014

Volltextzugriff (PDF)

Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure

Current cardiology reports, 2019-08, Vol.21 (8), p.70-70, Article 70

Scheen, André J.

2019

Volltextzugriff (PDF)

Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin

Expert opinion on drug metabolism & toxicology, 2010-10, Vol.6 (10), p.1265-1276

Scheen, André J

2010

Volltextzugriff (PDF)

An update on the safety of SGLT2 inhibitors

Expert opinion on drug safety, 2019-04, Vol.18 (4), p.295-311

Scheen, André J

2019

Volltextzugriff (PDF)

Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation)

Expert opinion on drug metabolism & toxicology, 2011-12, Vol.7 (12), p.1561-1576

Scheen, André J

2011

Volltextzugriff (PDF)

Lower limb amputations: protection with GLP-1 receptor agonists rather than increased risk with SGLT2 inhibitors?

Diabetes & metabolism, 2022-03, Vol.48 (2), p.101325-101325, Article 101325

Scheen, Andre J.

2022

Volltextzugriff (PDF)

A new paradigm for treating obesity and diabetes mellitus

Nature reviews. Endocrinology, 2015-04, Vol.11 (4), p.196-198

2015

Volltextzugriff (PDF)

Pharmacokinetic interactions with thiazolidinediones

Clinical pharmacokinetics, 2007, Vol.46 (1), p.1-12

SCHEEN, André J

2007

Volltextzugriff (PDF)

1 – 25 von 648

Menü

Weitere Dienste

Einstellungen

Cardiovascular effects of gliptins

Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue

Dipeptidylpeptitase-4 Inhibitors (Gliptins): Focus on Drug-Drug Interactions

Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease

Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations

SGLT2 Inhibitors as Add-On Therapy to Metformin for People with Type 2 Diabetes: A Review of Placebo-Controlled Trials in Asian versus Non-Asian Patients

Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus

Sibutramine on cardiovascular outcome

Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system

Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors

Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus

Time for reconciliation between cardiologists and diabetologists

Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor

Is there a role for α-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?

Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes

Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes

Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure

Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin

An update on the safety of SGLT2 inhibitors

Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation)

Lower limb amputations: protection with GLP-1 receptor agonists rather than increased risk with SGLT2 inhibitors?

A new paradigm for treating obesity and diabetes mellitus

Pharmacokinetic interactions with thiazolidinediones

Suchergebnisse filtern